A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

As the old saying goes, “an ounce of prevention is worth a pound of cure,” and in my decades of experience in healthcare that ...

In countless reports and studies, obesity is often reduced to just a number: 42% of adults in the U.S. have obesity, ...

A new University of Michigan study shows that a strong majority of older Americans want health insurance — including Medicare — to cover weight loss medica ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Fashion influencer Remi Bader just revealed she underwent a weight loss surgery that cut 80 percent of her stomach amid ...

State lawmakers are considering expanding the types of obesity treatments covered by Nevada Medicaid, including approving ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a ...